NuCana Past Earnings Performance
Past criteria checks 0/6
NuCana's earnings have been declining at an average annual rate of -7.5%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-7.5%
Earnings growth rate
3.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -741.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NuCana makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -28 | 6 | 28 |
| 31 Mar 24 | 0 | -27 | 6 | 25 |
| 31 Dec 23 | 0 | -28 | 6 | 25 |
| 30 Sep 23 | 0 | -35 | 6 | 31 |
| 30 Jun 23 | 0 | -33 | 7 | 31 |
| 31 Mar 23 | 0 | -31 | 7 | 34 |
| 31 Dec 22 | 0 | -32 | 7 | 36 |
| 30 Sep 22 | 0 | -30 | 8 | 34 |
| 30 Jun 22 | 0 | -34 | 8 | 35 |
| 31 Mar 22 | 0 | -39 | 9 | 38 |
| 31 Dec 21 | 0 | -41 | 9 | 37 |
| 30 Sep 21 | 0 | -39 | 8 | 34 |
| 30 Jun 21 | 0 | -40 | 8 | 31 |
| 31 Mar 21 | 0 | -36 | 8 | 29 |
| 31 Dec 20 | 0 | -31 | 7 | 26 |
| 30 Sep 20 | 0 | -26 | 7 | 23 |
| 30 Jun 20 | 0 | -22 | 6 | 22 |
| 31 Mar 20 | 0 | -20 | 6 | 21 |
| 31 Dec 19 | 0 | -21 | 6 | 20 |
| 30 Sep 19 | 0 | -17 | 6 | 19 |
| 30 Jun 19 | 0 | -16 | 5 | 18 |
| 31 Mar 19 | 0 | -13 | 5 | 17 |
| 31 Dec 18 | 0 | -14 | 5 | 17 |
| 30 Sep 18 | 0 | -15 | 4 | 16 |
| 30 Jun 18 | 0 | -26 | 7 | 23 |
| 31 Mar 18 | 0 | -28 | 5 | 20 |
| 31 Dec 17 | 0 | -23 | 5 | 18 |
| 30 Sep 17 | 0 | -20 | 4 | 16 |
| 30 Jun 17 | 0 | -7 | 1 | 8 |
| 31 Mar 17 | 0 | -6 | 1 | 8 |
| 31 Dec 16 | 0 | -6 | 1 | 8 |
| 31 Dec 15 | 0 | -5 | 1 | 6 |
Quality Earnings: N04 is currently unprofitable.
Growing Profit Margin: N04 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: N04 is unprofitable, and losses have increased over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare N04's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: N04 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: N04 has a negative Return on Equity (-741.68%), as it is currently unprofitable.